Effect of long-term oral administration of nicotinamide mononucleotide (NMN) on human health

Effect of long-term oral administration of nicotinamide mononucleotide (NMN) on human health - Effect of long-term oral administration of nicotinamide mononucleotide (NMN) on human health

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025739

Enrollment

Registered

2017-01-20

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Subjects receive 100 mg/day of NMN for 24 weeks. Subjects receive 200 mg/day of NMN for 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy

Exclusion criteria

Exclusion criteria: 1) Taking medicines for chronic disease 2) Taking functional food that may affect the trial 3) Participation in any clinical trial within 90 days of the commencement of the trial 4) History of hypersensitivity caused by NMN 5) In pregnancy or nursing a child 6) Judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
i) Serum or plasma concentration of the following parameters at baseline, weeks 4, 8, 12, 18, and 24. Thyroid-stimulating hormone (TSH) Free triiodothyronine (Free T3) Free thyroxine (Free T4) Growth hormone (GH) Prolactin Parathyroid hormone (PTH) Dehydroepiandrosterone sulfate (DHEA-S) Estradiol (E2) Testosterone Calcitonin Adrenocorticotropic hormone (ACTH) Arginine vasopressin (AVP) Cortisol Aldosterone Ghrelin Inhibin *Melatonin ii) Mitochondria activity in leucocyte at baseline and week 24. iii) Sirt1 and Sirt2 gene expressions in leucocyte at baseline and week 24.	—

Measure

Time frame

i) Serum or plasma concentration of the following parameters at baseline, weeks 4, 8, 12, 18, and 24. *Thyroid-stimulating hormone (TSH) *Free triiodothyronine (Free T3) *Free thyroxine (Free T4) *Growth hormone (GH) *Prolactin *Parathyroid hormone (PTH) *Dehydroepiandrosterone sulfate (DHEA-S) *Estradiol (E2) *Testosterone *Calcitonin *Adrenocorticotropic hormone (ACTH) *Arginine vasopressin (AVP) *Cortisol *Aldosterone *Ghrelin *Inhibin *Melatonin ii) Mitochondria activity in leucocyte at baseline and week 24. iii) Sirt1 and Sirt2 gene expressions in leucocyte at baseline and week 24.

—

Secondary

Measure	Time frame
Number and rate of adverse events.	—

Countries

Japan

Contacts

Public ContactFumiko Higashikawa

Hiroshima University, Institute of Biomedical & Health Sciences Project Research Center for Clinical Trial and Preventive Medicine

fumiko@hiroshima-u.ac.jp082-257-1533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026